New potential in pneumococcal immunization. Conjugate vaccine may improve disease protection, health of infants and young children.
Since 2000, a new pneumococcal conjugate vaccine has been on the US market, offering immunization against seven serotypes. Its use has the potential to dramatically reduce the incidence of pneumococcal disease and its sequelae in children. Here, the authors review the efficacy, safety, and cost of the new pneumococcal vaccine and offer guidelines on how to incorporate this newer vaccine into today's immunization regimens.
Garrison
Mark W
MW
Washington State University College of Pharmacy, Health Sciences Building, Box S, 310 N Riverpoint Blvd, Spokane, WA 99202-1675, USA. garrism@wsu.edu
Olds
Michael J
MJ
D002675:Child, Preschool; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control; D012449:Safety
D022242:Pneumococcal Vaccines